Particularly dynamic growth in the life sciences core sector, as a result of higher pharmaceutical sales and the Gerber acquisition, were the key driving forces behind the 11% sales growth achieved by Sandoz of Switzerland in 1994 expressed in local currency terms.
Group sales in 1994 were 15.9 billion Swiss francs ($12.4 billion), up 5% in Swiss francs.
Sales 1994 Sw Fr Local Mill Sw Fr Pharmaceuticals 7,196 -2% +4% Nutrition 2,771 +61% +67% Seeds 955 -3% +4% Life Sciences 10,922 +9% +15% Chemicals 2,324 -7% -1% Agro 1,368 +4% +9% Construction & 1,256 +2% +6% Environment Chemicals & 4,948 -2% +4% Environment Group Total 15,870 +5% +11%
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze